vTv Therapeutics (NASDAQ: VTVT) CEO gets 140,000 options

Rhea-AI Filing Summary

vTv Therapeutics Inc. reported an insider equity award for its President, CEO and Executive Chairperson, Paul J. Sekhri. On February 17, 2026, he was granted stock options tied to 140,000 shares of Class A common stock at an exercise price of $36.92 per share. The options vest 25% on the first anniversary of the grant date and then in equal quarterly installments. Following this grant, Sekhri’s directly held Class A interest reported in this filing totals 392,212 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SEKHRI PAUL J

(Last) (First) (Middle)

C/O VTV THERAPEUTICS INC.

3980 PREMIER DRIVE, SUITE 310

(Street)

HIGH POINT NC 27265

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
vTv Therapeutics Inc. [ VTVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Pres, CEO and Exec Chairperson

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Class A Common Stock	$36.92	02/17/2026		A		140,000		(1)	02/17/2036	Class A Common Stock ("Common Stock")	140,000	$36.92	392,212	D

Explanation of Responses:

1. The options vest 25% on the first anniversary of the grant date and in quarterly equal installments thereafter.

Remarks:

	/s/ Paul J. Sekhri	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did vTv Therapeutics (VTVT) report for Paul J. Sekhri?

vTv Therapeutics reported a grant of stock options to Paul J. Sekhri. He received options tied to 140,000 shares of Class A common stock as an equity award, increasing his directly reported Class A interest to 392,212 shares after the transaction.

How many vTv Therapeutics (VTVT) shares are covered by Paul Sekhri’s new option grant?

The new equity award covers 140,000 shares of Class A common stock. These are stock options, not currently issued shares, but they represent the right to acquire 140,000 shares subject to vesting and the stated exercise price.

What is the exercise price of Paul Sekhri’s vTv Therapeutics (VTVT) stock options?

The options have an exercise price of $36.92 per share. This means Sekhri can purchase each underlying share of Class A common stock at $36.92 once the options vest and are exercisable, subject to plan and award terms.

How do Paul Sekhri’s vTv Therapeutics (VTVT) options vest?

The options vest 25% after one year, then quarterly. Specifically, 25% vests on the first anniversary of the grant date, with the remaining 75% vesting in equal quarterly installments thereafter, encouraging longer-term alignment with company performance.

What is Paul Sekhri’s reported Class A stake in vTv Therapeutics (VTVT) after this grant?

After the grant, Sekhri’s directly reported Class A interest is 392,212 shares. This total reflects the holdings reported in the Form 4 following the 140,000-share stock option award on February 17, 2026.

Is Paul Sekhri’s vTv Therapeutics (VTVT) transaction a purchase or an award?

The transaction is an equity award, not an open-market purchase. It is coded as a grant or other acquisition of derivative securities (stock options), reflecting compensation rather than a discretionary market buy or sell.